# EDGAR Filing Document

**Accession Number:** 0001559356
**File Stem:** 0001493152-23-006801
**Filing Date:** 2023-3
**Character Count:** 4399
**Document Hash:** 27b1c65bbc377edf18bc7ac211a18132
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-006801.hdr.sgml**: 20230306

**ACCESSION NUMBER**: 0001493152-23-006801

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230306

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20230306

**DATE AS OF CHANGE**: 20230306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immune Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001559356
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 593226705
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-54933
- **FILM NUMBER:** 23709707

**BUSINESS ADDRESS:**
- **STREET 1:** 2431 ALOMA AVE #124
- **CITY:** WINTER PARK
- **STATE:** FL
- **ZIP:** 32792
- **BUSINESS PHONE:** (888) 613-8802

**MAIL ADDRESS:**
- **STREET 1:** 2431 ALOMA AVE #124
- **CITY:** WINTER PARK
- **STATE:** FL
- **ZIP:** 32792

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TNI BIOTECH, INC.
- **DATE OF NAME CHANGE:** 20121001

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 6, 2023 (February 28, 2023)

---

| |
|:---|
| **IMMUNE THERAPEUTICS, INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Florida** | **000-54933** | **59-3226705** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **2431 Aloma Ave., Suite 124, Winter Park, Florida** | **32792** |
| (Address of principal executive offices) | (Zip Code) |

---

---

| |
|:---|
| **888-391-9355** |
| (Registrant's telephone number, including area code) |

---

  <br> (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On February 28, 2023, shareholders holding approximately 50.58% of the outstanding common stock of Immune Therapeutics, Inc. (the "**Company**") executed a written consent (the "**Written Consent**") in lieu of a special meeting of the shareholders approving an amendment to the amended and restated articles of incorporation of the Company to change the Company's name to "Biostax Corp." (the "**Articles of Amendment**"). Pursuant to Rule 14c-2 of the Exchange Act of 1934, as amended, the Articles of Amendment may not become effective until at least 20 calendar days following the date on which an information statement informing shareholders of the Written Consent is first mailed to the Company's shareholders of record.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: March 6, 2023 | IMMUNE THERAPEUTICES, INC. |
|  | */s/ Kelly Wilson* |
|  | Name: Kelly Wilson |
|  | Title: Principal Executive Officer |

---